is a popular medicinal website in Bangladesh.



Generic name: Spironolactone & Furosemide
Manufacturer: Aristopharma Ltd.

Spironolactone is a long acting potassium diuretic and furosemide is a short-acting loop diuretic. Spironolactone and Furosemide have different but complementary mechanisms and site of action. Therefore, when given together they produce synergistic or additive diuretic effects. Spironolactone is a competitive inhibitor of the binding of aldosterone to its receptors. Its most important site of action is the distal portion of renal tubules. Spironolactone acts both as a diuretic and antihypertensive drug by antagonizing the sodium retaining effects of aldosterone.

Furosemide is a potent diuretic acting primarily on the medullary portion of the ascending limb of the Loop of Henle to inhibit a Na+/K+/2Cl- co-transporter which normally mediates ionic reabsorption. Furosemide inhibits sodium and potassium reabsorption by competing for the luminal face of epithelial cells and thereby removes the stimulus of water reabsorption. It also inhibits sodium reabsorption in other nephron segment.

Fruselac is indicated in the treatment of resistant oedema where this is associated with secondary hyperaldosteronism; conditions include chronic congestive heart failure and hepatic cirrhosis. Treatment with Fruselac should be reserved for cases refractory to a diuretic alone at conventional dosage. It is also indicated in the treatment of ascites. This combination should only be used if titration with the component drugs separately indicates that this product is appropriate.

Patients with prostatic hypertrophy or impairment of micturation have an increased risk of developing acute retention. Caution should also be exercised in the presence of liver disease as hepatic coma may be precipitated in susceptible cases. Caution should be observed in patients liable to electrolyte deficiency.


Post a Comment

Note: Only a member of this blog may post a comment.